GAMGERTAMIG
UNII SW2QD6CHA2
Substance Identification & Data
This profile provides standardized clinical and technical data for Gamgertamig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) SW2QD6CHA2.
Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3038119-48-8 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.
SW2QD6CHA2
3038119-48-8
N/A
Detailed Substance Profile
Preferred Name
GAMGERTAMIG
Official standardized name for this substance within the FDA UNII nomenclature system.
NCI Thesaurus
National Cancer Institute reference terminology for clinical and research data.
INN ID
13797
Sequential identifier assigned via the WHO International Nonproprietary Name program.
Substance Type
Gamgertamig
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).
Synonyms and Nomenclature
This section provides a complete list of nomenclature and identifier mappings for Gamgertamig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.
FDA Official Name
Gamgertamig
Common Names & Synonyms
H-gamma4 heavy chain anti-TNFRSF17 (H) (1-449) hole [VH (Homo sapiens IGHV7-4-1*02 (88.8%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [8.8.15] (26-33.51-58.97-111)) (1-122) -Homo sapiens IGHG4*01, nG4m(a) CH2 L92, 12-G4v5 h P10, 6-G4v3-44 CH2 E1.2, A114, 14-G4v75 CH3 C5, 14-G4v33 CH3 S22, A24, V86 (hole), 12-G4v6 CH3 K88(CH1 (123-220), hinge 1-12 S10>P (230) (221-232), CH2 L1.2>E (237), L92 (311), P114>A (331) (233-342), CH3 Y5>C (351), T22>S (368), L24>A (370), Y86>V (409), R88>K(411)(343-447), CHS (448-449)) (123-449)], (136-218')-disulfide with L-kappa light chain anti-TNFRSF17 (L') (1'-218') [V-KAPPA Musmus/Homsap (Mus musculus IGKV3-12*01 (91.9%) -IGKJ1*01 (83.3%) G120>Q (104'), L124>V (108')/Homo sapiens IGKV3D-11*02 (68.1%) -IGKJ1*01 (100%), CDR-IMGT [10.3.9] (27'-36'.54'-56'.93'-101')) (1'-111') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (157'), V101 (195') (112'-218')]; H-gamma4 heavy chain anti-CD3E (H'') (1''-452'') knob [VH Musmus/Homsap (Mus musculus IGHV10-1*04 (90.0%) -(IGHD) -IGHJ3*01 (93.3%) A128>S (125)/Homo sapiens IGHV3-72*01 (85.0%) -(IGHD) -IGHJ6*01 (90.9%) T123>L (120), CDR-IMGT [8.10.16] (26''-33''.51''-60''.99''-114'')) (1''-125'') -Homo sapiens IGHG4*01, nG4m(a) CH2 L92, 12-G4v5 h P10, 6-G4v3-44 CH2 E1.2, A114, G4v74 CH3 C10, 14-G4v32 CH3 W22 (knob), 12-G4v6 CH3 K88 (CH1 (126''-223''), hinge 1-12 S10>P (233'') (224''-235''), CH2 L1.2>E (240''), L92 (314''), P114>A (334'') (236''-345''), CH3 S10>C (359''), T22>W (371''), R88>K (414'') (346''-450''), CHS (451''-452'')) (126''-452'')], (139''-214''')-disulfide with L-lambda2 light chain anti-CD3E (L''') (1'''-215''') [V-lambda Musmus/Homsap (Mus musculus IGLV1*01 (81.2%) -IGLJ1*01 (100%)/Homo sapiens IGLV7-46*01 (77.9%) -IGLJ3*02 (100%), CDR-IMGT[9.3.9] (26'''-34'''.52'''-54'''.91'''-99''')) (1'''-109''') -Homo sapiens IGLC2*01 (100%) (C-LAMBDA2) (110'''-215''')]; dimer (228-231'':231-234'':351-359'')-trisdisulfide, produced in Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1, lacking the glutamine synthetase (GS-KO) gene, glycoform alfa
Immunoglobulin G4, bispecific, [233-proline,240-glutamic acid,334-alanine,359-cysteine,371-tryptophan,414-lysine], anti-(human CD antigen ε-chain [4-leucine]) (human-Mus musculus monoclonal hSP34 H9K5 γ4-chain), (139-214′′′)-disulfide with human-Mus musculus monoclonal hSP34 H9K5 λ-chain, (231→228′),(234→231′),(359→351′)-tris(disulfide) with immunoglobulin G4 [230-proline,237-glutamic acid,331-alanine,351-cysteine,368-serine,370-alanine,409-valine,411-lysine] anti-(human tumor necrosis factor receptor superfamily protein TNFRSF17) (human-Mus musculus monoclonal h29A11 H3K2 γ4-chain), (136′→218′′)-disulfide with human-Mus musculus monoclonal h29A11 H3K2 κ-chain
gamgertamig [INN]
immunoglobulin (H-gamma4_L-kappa)_(H-gamma4_L-lambda2), anti-[Homo sapiens TNFRSF17 (tumor necrosis factor (TNF) receptor superfamily member 17, B cell maturation antigen, BCMA, TNFRSF13A, CD269)] and anti-[Homo sapiens CD3E (CD3 epsilon, Leu-4)], monoclonal antibody, bispecific, bivalent (gamgertamig)
